Cell line · CVCL_2420
Papers40
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 40
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids. | Clin Proteomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Steroid-Metabolizing Enzymes with 15β-Substituted Estrone Analogues: Dual Discovery of AKR1C2/17β-HSD1 Inhibitors and a Fluorescent 17β-HSD1 Ligand. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis. | Biomedicines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer. | Ther Adv Med Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic modulation of BARD1 to enhance anti-VEGF therapy. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. | NPJ Precis Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation. | J Ovarian Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers. | Nucleic Acids Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Physiological Concentrations of Cimicifuga racemosa Extract Do Not Affect Expression of Genes Involved in Estrogen Biosynthesis and Action in Endometrial and Ovarian Cell Lines. | Biomolecules | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells. | Front Oncol | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2420/papers